# Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)

> **NCT02625610** · PHASE3 · COMPLETED · sponsor: **EMD Serono Research & Development Institute, Inc.** · enrollment: 499 (actual)

## Conditions studied

- Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction

## Interventions

- **DRUG:** Avelumab
- **DRUG:** Oxaliplatin
- **DRUG:** 5-Fluorouracil
- **DRUG:** Leucovorin
- **DRUG:** Capecitabine
- **OTHER:** Best supportive care
- **DRUG:** Oxaliplatin
- **DRUG:** 5-Fluorouracil
- **DRUG:** Leucovorin
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT02625610
- **Lead sponsor:** EMD Serono Research & Development Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-24
- **Primary completion:** 2019-09-13
- **Final completion:** 2021-06-03
- **Target enrollment:** 499 (ACTUAL)
- **Last updated:** 2022-06-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02625610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02625610, "Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02625610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*